|118.19||+0.6500||+0.55%||Vol 4.40M||1Y Perf 20.78%|
|Jul 23rd, 2021 16:02 DELAYED|
|- -||-0.24 -0.20%|
|Target Price||120.62||Analyst Rating||Moderate Buy 1.64|
|Potential %||2.06||Finscreener Ranking||★+ 43.17|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 45.59|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 49.02|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★+ 41.79|
|Market Cap||208.75B||Earnings Rating||Neutral|
|Price Range Ratio 52W %||98.79||Earnings Date||30th Jul 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||30th Jul 2021|
|Estimated EPS Next Report||3.11|
|EPS Growth Next 5 Years %||5.30|
|Avg. Weekly Volume||5.23M|
|Avg. Monthly Volume||6.01M|
|Avg. Quarterly Volume||6.36M|
AbbVie Inc. (NYSE: ABBV) stock closed at 118.19 per share at the end of the most recent trading day (a 0.55% change compared to the prior day closing price) with a volume of 4.41M shares and market capitalization of 208.75B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 47000 people. AbbVie Inc. CEO is Richard A. Gonzalez.
The one-year performance of AbbVie Inc. stock is 20.78%, while year-to-date (YTD) performance is 10.3%. ABBV stock has a five-year performance of 85.22%. Its 52-week range is between 79.11 and 118.67, which gives ABBV stock a 52-week price range ratio of 98.79%
AbbVie Inc. currently has a PE ratio of 42.40, a price-to-book (PB) ratio of 15.14, a price-to-sale (PS) ratio of 5.13, a price to cashflow ratio of 11.00, a PEG ratio of 2.32, a ROA of 4.12%, a ROC of 8.29% and a ROE of 175.15%. The company’s profit margin is 15.15%, its EBITDA margin is 29.50%, and its revenue ttm is $39.77 Billion , which makes it $22.52 revenue per share.
Of the last four earnings reports from AbbVie Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.11 for the next earnings report. AbbVie Inc.’s next earnings report date is 30th Jul 2021.
The consensus rating of Wall Street analysts for AbbVie Inc. is Moderate Buy (1.64), with a target price of $120.62, which is +2.06% compared to the current price. The earnings rating for AbbVie Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AbbVie Inc. has a dividend yield of 4.51% with a dividend per share of $5.20 and a payout ratio of 173.00%.
AbbVie Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.76, ATR14 : 1.71, CCI20 : 103.62, Chaikin Money Flow : 0.30, MACD : 0.83, Money Flow Index : 73.64, ROC : 1.23, RSI : 61.49, STOCH (14,3) : 90.26, STOCH RSI : 1.00, UO : 57.26, Williams %R : -9.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AbbVie Inc. in the last 12-months were: Azita Saleki-Gerhardt (Option Excercise at a value of $3 152 428), Azita Saleki-Gerhardt (Sold 109 146 shares of value $12 265 108 ), Carlos Alban (Option Excercise at a value of $4 155 980), Carlos Alban (Sold 115 830 shares of value $11 583 000 ), Carrie C. Strom (Option Excercise at a value of $173 176), Carrie C. Strom (Sold 4 184 shares of value $470 282 ), Elaine K. Sorg (Option Excercise at a value of $1 813 052), Elaine K. Sorg (Sold 28 635 shares of value $3 031 374 ), Henry O. Gosebruch (Sold 40 000 shares of value $3 975 046 ), Jeffrey Ryan Stewart (Option Excercise at a value of $2 600 822), Jeffrey Ryan Stewart (Sold 64 353 shares of value $6 806 475 ), Michael Severino (Sold 90 679 shares of value $8 488 461 ), Richard A. Gonzalez (Option Excercise at a value of $20 422 257), Richard A. Gonzalez (Sold 401 717 shares of value $40 913 456 ), Timothy J. Richmond (Option Excercise at a value of $2 673 325), Timothy J. Richmond (Sold 71 504 shares of value $7 577 990 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.